CK 0803
Alternative Names: CK-0803Latest Information Update: 31 Aug 2023
At a glance
- Originator Cellenkos
- Class Antiparkinsonians; T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
- Preclinical Chronic inflammatory demyelinating polyradiculoneuropathy; Parkinson's disease
Most Recent Events
- 31 Aug 2023 Preclinical trials in Parkinson's disease in USA (Parenteral) (Cellenkos pipeline, August 2023)
- 03 Apr 2023 Cellenkos initiates a phase I REGAL trial for Amyotrophic lateral sclerosis (In adults, In the elderly) in USA (IV, Infusion) (NCT05695521)
- 21 Sep 2022 US FDA approves IND application for CK 0803 for phase-I trial in Amyotrophic lateral sclerosis